Louis Navellier’s #1 Stock for 2022

On October 20, the man who recommended Google before anyone else will reveal his #1 stock pick for 2022 — for FREE — ticker symbol and all — in a special presentation.

Wed, October 20 at 4:00PM ET
 
 
 
 

8 Pharmaceutical Stocks to Buy Now

This week, eight pharmaceutical stocks are improving their overall rating on Portfolio Grader. Each of these rates an “A” (“strong buy”) or “B” overall (“buy”).

NuPathe Inc. (PATH) is bettering its rating of C (“hold”) from last week to a B (“buy”) this week. In Portfolio Grader’s specific subcategories of Earnings Momentum and Earnings Revisions, PATH also gets A’s. NuPathe develops pharmaceutical products used for the treatment and management of neurological and psychiatric diseases. For more information, get Portfolio Grader’s complete analysis of PATH stock.

GW Pharmaceuticals PLC Sponsored ADR (GWPH) gets a higher grade this week, advancing from a C last week to a B. For more information, get Portfolio Grader’s complete analysis of GWPH stock.

This week, Watson Pharmaceuticals (WPI) is making solid headway. The company’s rating improves to an A (“strong buy”) from last week’s B (“buy”) rating. Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock.

Lipocine, Inc. (LPCN) earns an A this week, jumping up from last week’s grade of B. Lipocine is engaged in the development of pharmaceutical products in the areas of men’’s and women’’s health. For more information, get Portfolio Grader’s complete analysis of LPCN stock.

Paratek Pharmaceuticals Inc (PRTK) boosts its rating from a B to an A this week. For more information, get Portfolio Grader’s complete analysis of PRTK stock.

Pain Therapeutics, Inc.’s (PTIE) ratings are looking better this week, moving up to an A from last week’s B. Pain Therapeutics develops safer or more efficacious drugs for use in pain management, particularly in the area of opioid painkillers. For more information, get Portfolio Grader’s complete analysis of PTIE stock.

This week, Cardiome Pharma (CRME) pushes up from a C to a B rating. Cardiome Pharma focuses on the discovery, development, and commercialization of drugs to treat or prevent cardiovascular and other diseases. For more information, get Portfolio Grader’s complete analysis of CRME stock.

AbbVie, Inc. (ABBV) improves from a C to a B rating this week. AbbVie, a research-based biopharmaceutical company, engages in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. For more information, get Portfolio Grader’s complete analysis of ABBV stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2015/09/8-pharmaceutical-stocks-to-buy-now-path-gwph-wpi-2/.

©2021 InvestorPlace Media, LLC